Cemiplimab significantly improved disease-free survival in high-risk CSCC patients, with a 24-month survival rate of 87% compared to 64% for placebo. The phase 3 C-POST trial showed cemiplimab's ...
Approval based on pivotal Phase 3 C-POST trial showing Libtayo significantly reduced the risk of disease recurrence or death by 68% compared to placebo (hazard ratio: 0.32; 95% confidence interval: ...
Clinicians must consider patient comorbidities and therapy safety when selecting immunotherapy for cSCC, says Todd ...
Libtayo demonstrated a 68% reduction in the risk of disease recurrence or death, the primary endpoint of the trial (p<0.0001) Libtayo also demonstrated 80% and 65% reductions in the risk of ...
The median disease-free survival was not reached in the cemiplimab arm and was 49.4 months in the placebo arm. Adjuvant cemiplimab can improve disease-free survival (DFS) in patients with cutaneous ...
The FDA has approved cemiplimab (Libtayo, Regeneron) for the adjuvant treatment of adults with cutaneous squamous cell carcinoma (CSCC) at a high risk for recurrence after surgery and radiation. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results